The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTXin Vitroandin Vivo

Abstract

CIK cells plused with docetaxel demonstrated a prominent augmentation of antitumor activity against multidrug resistance lung adenocarcinoma cell lines both in vitro and in vivo.

Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies

“…Immunotherapy stimulating the immune system and enhancing the patient's own anti-tumor ability is an alternative and promising way to treat cancer and overcome chemotherapy drug resistance [9,10]. In the 1980s, the lymphocytes activated by IL-2, were used for treating malignancies at advanced stage [11][12][13].…”

“…Currently, CIK cells transfusion has evolved to become a promising way for overcoming chemotherapy resistance [9,10]. Liu et al reported that CIK cells possessed a higher antitumor cytotoxic activity against a drug-resistant lung adenocarcinoma cell line in vitro and they found CIK cells plused with docetaxel demonstrated a prominent augmentation of antitumor activity against multidrug resistance lung adenocarcinoma cell lines both in vitro and in vivo [10].…”

“…Liu et al reported that CIK cells possessed a higher antitumor cytotoxic activity against a drug-resistant lung adenocarcinoma cell line in vitro and they found CIK cells plused with docetaxel demonstrated a prominent augmentation of antitumor activity against multidrug resistance lung adenocarcinoma cell lines both in vitro and in vivo [10]. Since most of the clinical studies so far showed that the efficiencies of CIK cells especially autologous ones to treat human malignancies were low [37,38] and studies have showed that CB-CIK cells are more potent in cytotoxic activity against various tumor cells than autologous ones with similar phenotype both in vitro and in vivo, we hypothesized CB-CIK cells could act synergistically with chemotherapeutic agents on malignant cells after first-line chemotherapy failure and CB-CIK cells might help second-line chemotherapeutic agents to overcome cancer cells' drug resistance, and thus improve PFS and median survival of patients with advanced solid malignancies.…”

Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients

“…Small remnant lesions in situ and metastatic cancer cells are the main reasons for recurrence. Immunotherapy, using various methods to restore and enhance the immune abilities of patients to eliminate cancer cells, is an alternative and promising option in treating cancers (Liu et al, 2009). Immunotherapy overcomes immunosuppression induced by cancer, surgery, or chemotherapeutic agents (Shi et al, 2012).…”

“…Synergistic use of CIK cells and docetaxel demonstrated a stronger anti-tumor effect in several multidrug-resistant lung adenocarcinoma cell lines (Liu et al, 2009). The property of antagonistic drug resistance of DC-CIK cells makes it appropriate for improving the clinical outcome of chemotherapy.…”